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Take-home message  
Living in tropical Australia was associated with NTM acquisition whilst long-term 
azithromycin was protective in CF. 
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Word count, 1195 
To the editor:  
Improved survival rates and increased treatment intensity of people with cystic fibrosis 
(CF) has been accompanied by the rising incidence of multi-antibiotic resistant and 
difficult to treat respiratory pathogens, including non-tuberculous mycobacteria (NTM) 
[1]. NTM epidemiology in CF varies globally with a prevalence of >20% in some 
geographical locations [2]. In particular, there are concerns that active NTM disease 
from rapidly growing mycobacteria (Mycobacterium abscessus complex) may be 
increasing and causing accelerated pulmonary decline [3, 4]. NTM are found naturally 
in ecological niches such as soil and water and susceptible individuals may also 
acquire infection from potable water in their homes [5, 6]. Recent reports demonstrate 
person-to-person transmission [7, 8], which might occur via fomites and cough 
aerosols [8] and further emphasise the potential clinical importance of these 
organisms. 
 
The principle aim of this observational study was to determine predictors of NTM 
acquisition in the adult CF patient cohort at The Prince Charles Hospital (TPCH) in 
Queensland, Australia. The study was approved by TPCH Human and Research 
Ethics Committee, Metro North Hospital and Health Service, Queensland, Australia 
(HREC/13/QPCH/51). 
 
CF patients (n=434) receiving their care at TPCH between 2001-2013 were included. 
Patients were stratified into one of two cohorts depending on whether they were NTM 
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positive or negative (naïve) based on sputum culture results, which were available for 
399/434 (92%) patients. The remaining patients (n=35) who were not screened for 
NTM during the study period were classed as NTM naïve. Mycobacterial culture and 
species identification methods are described previously [9]. The date of NTM 
acquisition was defined as the date of first positive culture identified by the Queensland 
Mycobacterial Reference Laboratory or the referring CF centre (if patient was 
transferred to TPCH). Active NTM disease was defined according to American 
Thoracic Society guidelines [10].  
 
Clinical and demographic data (Table 1) were collected from medical records, the 
referring CF centre or the Australian CF Data Registry. For NTM positive patients, 
these data correlated with the date of NTM acquisition. In NTM naïve patients, data 
corresponded to the calendar year prior to 1st January 2013 or year prior to death 
(n=43) or lung transplantation (n=72). Data could not be retrieved for NTM naïve 
patients, who had not attended the clinic during 2012 (previously moved 
interstate/overseas or lost to follow-up). 
 
TPCH is uniquely situated geographically with a catchment area of 1.8 million km2 
including zones north (tropical) and south (sub-tropical) of the Tropic of Capricorn 
(Latitude 23.5° south of the Equator). Therefore, residential location for each person 
was defined as tropical or sub-tropical according to residence in the five years prior to 
(i) the date of NTM acquisition or (ii) 1st January 2013, death (n=43), or lung 
transplantation (n=72) if NTM naïve. Patients who resided in both zones during these 
five years were excluded from further analyses (n=9).  
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Categorical data were analysed using a chi-square test with Yates continuity 
correction or Fisher’s exact test, as appropriate. Univariable and multivariable logistic 
regression analysis was performed to identify factors associated with NTM acquisition 
based on complete data from 375 patients. Variables with P<0.1 were included in the 
multivariable model. Cox regression survival analysis was used to assess the 
association between NTM acquisition and active NTM disease (both modelled as time 
dependent covariates) and time to death or lung transplantation (based on the entire 
CF cohort with all data censored to December 2013). Data were analysed using Stata 
v14 (StataCorp) or SPSS v22 (IBM). 
 
Spatial clustering of NTM has been reported in the United States with western and 
southeastern states designated high-risk areas and associated with high surface water 
and atmospheric moisture availability [11]. In our study, NTM was detected in 54/375 
(14%) patients with CF. In a multivariable logistic regression, the odds of NTM 
acquisition were 2.5 (95% confidence interval, 1.2-5.4) times higher (Table 1) in those 
who resided in the tropical (n=19/70, 27%) compared to the sub-tropical zone 
(n=35/305, 11%).  
 
Factors such as heightened clinician awareness, increased surveillance practices, and 
improved culture procedures have likely contributed to increased detection and 
identification of NTM [4, 12]. At TPCH, the percentage of sputum samples screened 
for NTM increased by >60% between 2001-2013. The mean number of sputum 
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samples per person that underwent NTM screening was similar between the tropical 
(2.8 sputum/person/year) and sub-tropical (2.5 sputum/person/year) patients.  
 
Mycobacterial species identification was available for 72/73 (99%) isolates and a 
quarter of NTM positive patients acquired more than one NTM species during the 
study period (tropical patients: n=6/70, 9%; sub-tropical patients: n=7/305, 2%; 
P=0.02) with a range of 1-4 species identified per person, potentially adding to the 
complexity when selecting treatment. The most commonly identified NTM species 
were M. abscessus complex (n=33/73, 45%) and the slowly growing species, 
Mycobacterium intracellulare (n=23/73, 32%). Previously, spatial clusters of these 
NTM species were found in Queensland (M. abscessus complex, coastal Whitsunday 
region, tropical zone; M. intracellulare, agricultural Darling Downs region, subtropical 
zone) [9]. When the primary NTM species acquired was considered for each CF 
patient, an association between M. abscessus complex and geographical zone was 
observed (P=0.02) with a higher recovery from tropical patients (n=10/70, 14%) than 
sub-tropical patients (n=17/305, 6%). Conversely, there was no association between 
M. intracellulare acquisition and geographical zone (tropical patients, n=6/70, 9%; sub-
tropical patients, n=10/305, 3%; P=0.09).  Further studies are required to determine 
the specific regions within each zone, which are high risk for acquisition of a particlar 
NTM species in CF. Other rapidly growing species identified were Mycobacterium 
chelonae (n=2) and Mycobacterium fortuitum (n=3) and the remaining slowly growing 
species included Mycobacterium avium (n=6), Mycobacterium scrofulaceum (n=2), 
Mycobacterium lentiflavum (n=1), Mycobacterium simiae (n=1) and Mycobacterium 
shimoidei (n=1).  
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NTM lung disease was reported to occur in 69% of M. abscessus infected CF patients 
[4]. Here, active NTM disease was diagnosed in 14/70 (20%) tropical patients and 
11/305 (4%) sub-tropical patients (P<0.001) and overall, 23/25 (92%) people 
diagnosed with lung disease were positive for M. abscessus complex.  
 
Markers for severe CF disease (e.g. pancreatic insufficiency, minimal CFTR function, 
P. aeruginosa infection) have also been reported to coincide with higher rates of NTM 
infection [4]. Whilst we did not find that such markers were associated with NTM 
acquisition (Table 1) after adjustment for other variables, we found that macrolide 
treatment for at least 6 months in the prior year was associated with reduced NTM 
acquisition. The adjusted odds of NTM acquisition was 15.4 (95% confidence interval, 
7.8-30.5) times higher in those who were not prescribed azithromycin compared to 
those that were (Table 1). The role of macrolide antibiotic use in NTM infection remains 
controversial with one study suggesting enhanced risk of NTM and others refuting this 
claim [13-15].  
 
The impact of NTM infection and patient survival is currently unclear. One study 
observed that a quarter of patients with M. abscessus complex died or were lung 
transplanted [12]. Here, neither being NTM positive (hazards ratio, 0.6; 95% 
confidence interval, 0.2-1.4; P=0.2) nor being diagnosed with active NTM disease 
(hazards ratio, 0.6; 95% confidence interval, 0.2-2.6; P=0.5) were associated with an 
increased risk of death/lung transplantation. 
 
Although this study is limited by its retrospective cross-sectional design, we found that 
living in the tropical zone of Australia was independently associated with NTM 
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acquisition whilst long-term azithromycin treatment was protective. Tropical patients 
were more likely to acquire more than one NTM species and have a diagnosis of active 
NTM disease. Australian population-based studies are required to determine specific 
host, socio-ecological, economic, climatic and environmental factors that affect 
acquisition and development of active NTM disease in CF.  
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TABLE 1. Logistic regression analysis of predictor variables associated with NTM 
acquisition (n=375). 
Univariable model 
Odds ratio 
(95% CI) 
P-value
Age (per 10 years) 0.7 (0.5-0.9) 0.02 
Gender 1.0 (0.6-1.8) 1.0 
CFTR functionŦ   
- Residual versus minimal 1.3 (0.5-3.8) 0.6 
- Non-classified versus minimal 0.6 (0.3-1.2) 0.2 
Tropical residence in the previous 5 years 2.9 (1.5-5.4) 0.001 
Chronic Pseudomonas aeruginosa infection 0.6 (0.3-1.4) 0.2 
FEV1% predicted (per 10% increase) 1.2 (1.1-1.4) <0.001 
Pancreatic sufficiency status 0.5 (0.2-1.0) 0.04 
Not prescribed azithromycin >6 months in the previous year  15.7 (8.1-30.6) <0.001 
Hospital admissions in the previous year (per 5 admissions) 0.3 (0.1-0.7) 0.003 
Hospital days in the previous year (per 10 hospital days) 0.8 (0.7-0.9) 0.002 
 
Multivariable model* 
Odds ratio  
(95% CI) 
P-value
Age (per 10 years) 0.7 (0.5-1.0) 0.03 
Tropical residence in the previous 5 years 2.5 (1.2-5.4) 0.02 
Not prescribed azithromycin for >6 months in the previous year  15.4 (7.8-30.5) <0.001 
 
CFTR, cystic fibrosis transmembrane conductance regulator; FEV1 % predicted, forced 
expiratory volume in the first second percentage predicted; CI, confidence interval. 
* Final model shows predictor variables that retained a significant association with NTM 
acquisition after adjustment for all other factors. 
Ŧ Definitions of CFTR function: Residual function, harbouring ≥1 allele with Class IV-V 
mutations; Minimal function, harbouring two alleles with Class I-III mutations; Non-classified, 
harbouring two alleles with mutations of unknown function. 
